Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 3(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01675999Phase 2Unknown

Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer

Role: collaborator

NCT00189631Phase 3Unknown

UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy

Role: lead

NCT00189657Phase 3Unknown

5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer

Role: lead

NCT00189670Phase 2Completed

Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer

Role: lead

NCT00189683Phase 3Unknown

Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy

Role: lead

NCT00189644Phase 3Unknown

6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer

Role: lead

All 6 trials loaded